Felicia Cosman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 . ObsEva SAApril 27, 2021 GMT - women Phase 3 -   GENEVA, Switzerland and BOSTON, MA – April 27, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the initiation of the observational PRIMROSE 3 study. PRIMROSE 3 will evaluate long-term bone mineral density (BMD) in subjects who completed at least 20 weeks of treatment in the Phase 3 PRIMROSE 1 (US only) and PRIMROSE 2 (Europe and EU) studies. “GnRH antagonists are an exciting new therapeutic approach for the treatment of uterine fibroids. In the setting of dose-dependent reductions in estradiol, it is important to understand changes in bone mineral density following treatment, especially amongst potentially

United statesShauna dillonBrian ocallaghanJoyce allaireFelicia cosmanSwiss exchangeOffice contactColumbia universityBriano callaghanNasdaq global select marketUnmet medicalPrivate securities litigation reform actRisk factorsAnnual reportஒன்றுபட்டது மாநிலங்களில்ஷ்ௌுனா டில்லன்